AlveoliX

AlveoliX AG is a biotechnology startup based in Switzerland, founded in 2019. The company's slogan "In-vitro models inspired by nature Ι Organs-on-Chip" encapsulates its vision and mission. AlveoliX aims to revolutionize drug development research by providing in-vitro models, known as organ-on-chips, that faithfully replicate the in-vivo environment. These models have the potential to enhance the predictability of drugs' responses in humans compared to traditional in-vitro and in-vivo models, consequently reducing the reliance on animal testing. The company's mission is to offer in-vitro solutions leveraging proprietary organ-on-chip technologies to improve preclinical decision-making and drive down drug development costs. Notably, AlveoliX received a grant investment from Eurostars on 19th March 2019, indicating early recognition and support for their innovative approach. This forward-looking investment aligns with the growing emphasis on ethical and effective drug development practices. AlveoliX's creation of in-vitro models that closely mirror human physiology holds promise for transforming the pharmaceutical industry.